Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is Dificid better than Flagyl for C. diff?How does lipitor's protein binding impact kidney dialysis?How does Perjeta work with Herceptin?What is the dosing for Saphnelo?How does st john's wort alter lipitor's effectiveness?
See the DrugPatentWatch profile for Perjeta
Perjeta Patent Expiry and Impact Perjeta, also known as pertuzumab, is a popular cancer medication used in combination with Herceptin (trastuzumab) and chemotherapy to treat certain types of breast cancer. It is a targeted therapy designed to prevent the growth and spread of cancer cells by blocking specific proteins. When Does Perjeta Patent Expire? According to the patent database on DrugPatentWatch.com [1], the original patent for Perjeta (pertuzumab) expired in the United States on November 29, 2026 [1]. However, generic versions may not enter the market immediately due to a pending patent extension and other barriers. Patent Extensions and Biosimilars The manufacturer, Roche, has obtained an extension of the original patent for Perjeta in the US through the Patent Term Adjustment (PTA) provision [1]. This PTA extension extends the patent term until June 2028 [1]. Biosimilar versions of Perjeta are awaiting approval by regulatory agencies and may enter the market in the coming years. Comparison with Other Medications Perjeta is often used in combination with Herceptin to treat HER2-positive breast cancer. The combination has been shown to improve outcomes compared to Herceptin alone [2]. Other cancer medications, such as Keytruda (pembrolizumab), also treat HER2-positive breast cancer but work through a different mechanism [3]. Regulatory Status and Availability Perjeta is approved in over 100 countries, including the US and Europe, for the treatment of HER2-positive breast cancer [4]. However, the availability and pricing of the medication may vary depending on the country and regulatory agency. Patient Concerns and Side Effects Common side effects of Perjeta include diarrhea, fatigue, and rash [5]. Patients should discuss potential side effects and the efficacy of the medication with their healthcare provider before starting treatment. Sources [1] DrugPatentWatch.com - Perjeta (Pertuzumab) Patent Expiration [2] New England Journal of Medicine - Overall Survival in Her2-positive Breast Cancer [3] Keytruda (Pembrolizumab) - FDA Approval Brochure [4] Roche Pharmaceuticals - Perjeta (Pertuzumab) Regulatory Approval [5] Perjeta (Pertuzumab) - Prescribing Information
Other Questions About Perjeta :